Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × ARQ531 × 90 days × Clear all

NCT07583810 2026-05-15

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, B-Cell, Marginal Zone